Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMLA vs ALPHACAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Topical anesthesia of intact skin for superficial procedures,Topical anesthesia of genital mucous membranes for minor superficial procedures,Local analgesia prior to lumbar puncture (off-label),Local analgesia prior to vaccination (off-label)
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
After topical application, the terminal elimination half-life of lidocaine is approximately 1.5-2 hours; prilocaine half-life is approximately 1.5 hours. In neonates, half-life may be prolonged due to immature hepatic function. Clinical context: Steady state is achieved within 12-24 hours with repeated application.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Lidocaine is primarily metabolized by CYP1A2 to monoethylglycinexylidide (MEGX) and further by CYP3A4; prilocaine is metabolized by amidases to o-toluidine metabolites that can oxidize hemoglobin to methemoglobin.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Lidocaine and prilocaine are metabolized in the liver; lidocaine metabolites (primarily 4-hydroxyxylidine) and prilocaine metabolites (primarily o-toluidine) are excreted renally. Less than 5% of unchanged lidocaine and prilocaine are excreted unchanged in urine. Fecal excretion is negligible.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Lidocaine: 65-70% bound to alpha-1-acid glycoprotein and albumin. Prilocaine: 55% bound to albumin.
90-95% bound to alpha-1-acid glycoprotein and albumin.
Lidocaine: Vd approximately 1.0-1.5 L/kg; prilocaine: Vd approximately 1.5-2.0 L/kg. Clinical meaning: Large Vd indicates extensive tissue distribution, including into the CNS and adipose tissue.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Topical bioavailability: 20-30% for lidocaine and prilocaine when applied to intact skin under occlusion; higher (up to 80%) on mucous membranes or abraded skin. Systemic absorption is minimal with recommended doses, but can be significant with prolonged application or large surface areas.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment due to potential accumulation of lidocaine and prilocaine metabolites.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
In Child-Pugh Class B or C, use with caution and consider reduced application area or shorter application time due to reduced metabolism of lidocaine and prilocaine; specific dose modifications not established.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
Infants and children: Apply 1-2 g per 10 cm², with maximum application area based on weight: 10 cm² for infants 1-3 months, 20 cm² for 3-12 months, 100 cm² for 1-6 years, 200 cm² for 7-12 years; application time 30-60 minutes depending on age and procedure.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
No specific dose adjustment; use with caution in elderly due to increased risk of systemic absorption from thinner skin and potential comorbidities; consider smaller application area or shorter duration.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
EMLA cream can cause methemoglobinemia, especially in children under 12 months, patients with glucose-6-phosphate dehydrogenase deficiency, or those taking oxidizing drugs. Serious and fatal methemoglobinemia has been reported; monitor for signs and symptoms.
Not available.
Avoid application to open wounds, mucous membranes (except genital), or areas with altered skin barrier. Use with caution in patients with severely traumatized mucosa or sepsis. Monitor for methemoglobinemia, especially in young children. Do not apply to large areas or for prolonged periods. Consider risk of systemic toxicity if applied to inflamed skin or large areas.
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Hypersensitivity to lidocaine, prilocaine, or other amide anesthetics; known history of methemoglobinemia; application to eyes or on tympanic membrane; patients with severe hepatic disease (due to impaired metabolism).
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
No known food interactions. Avoid alcohol if large amounts of lidocaine/prilocaine are absorbed (rare).
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in human data. Second and third trimesters: no known fetal harm from topical use. Methemoglobinemia risk in fetus if high doses or prolonged use, especially with prilocaine.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Lidocaine and prilocaine are excreted into breast milk in low amounts. M/P ratio: lidocaine ~0.4-0.6, prilocaine ~1.0-1.4. Infant dose ~1-2% of maternal weight-adjusted dose. Risk of methemoglobinemia in premature or G6PD-deficient infants. Use with caution.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
No specific dose adjustments required for topical application. Physiologic changes in pregnancy (increased plasma volume, decreased protein binding) do not significantly alter systemic absorption from intact skin. Avoid large areas, prolonged application, or abraded skin to minimize systemic load.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
EMLA (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) requires at least 60 minutes of occlusive application for dermal analgesia. Apply to intact skin only; avoid mucous membranes due to rapid absorption. Do not use in infants <37 weeks postconceptual age due to methemoglobinemia risk. Maximum application area: 10% body surface in infants. Onset is slower on thicker skin (e.g., back vs. antecubital). Remove cream after 4 hours to prevent systemic toxicity.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Apply a thick layer (1-2 mm) to intact skin and cover with occlusive dressing for at least 60 minutes before procedure.,Do not use on broken skin, eyes, or near mucous membranes.,Wash hands after application and avoid touching eyes.,Remove cream and dressing just before procedure; do not leave on longer than 4 hours.,Possible mild skin reactions: blanching, redness, swelling. Serious allergic reactions are rare but seek medical help if difficulty breathing or hives occur.,Inform your doctor if you have liver disease, G6PD deficiency, or are taking other numbing medicines.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMLA vs ALPHACAINE HYDROCHLORIDE, answered by our medical review team.
EMLA is a Local Anesthetic that works by EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.. ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMLA and ALPHACAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMLA is: Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.. The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMLA and ALPHACAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMLA is classified as Category C. EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in . ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.